@article{41f67f9c638d410f87d0774544278465,
title = "Identification of a naturally occurring 21 bp deletion in alpha2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment",
abstract = "Neurocognitive deficits are recognized as a cardinal feature of schizophrenia. Atypical antipsychotics have high affinity for many neurotransmitter receptors. Among these receptors, antipsychotics are antagonists of adrenoceptors, and this pharmacological property has been postulated to be involved in the mechanism of action of antipsychotics. We tested the hypotheses that clinical response and cognitive improvement to antipsychotic treatment are associated with genetic variation in adrenergic α2C receptor (ADRA2C). Fifty-seven patients with chronic schizophrenia were prospectively assessed for clinical response to antipsychotic treatment. They were subsequently genotyped for a 21 bp insertion/deletion that we identified in the 3′ untranslated region (3′UTR) of ADRA2C. With regard to clinical response and cognitive improvement to antipsychotics, there was no significant association observed for this polymorphism. Our results suggest that the novel polymorphism may not play a major role in antipsychotic response.",
keywords = "Adrenergic α receptor (ADRA2C), Antipsychotic response, Cognition, Polymorphism, Schizophrenia",
author = "{De Luca}, Vincenzo and Vincent, {John B.} and M{\"u}ller, {Daniel J.} and Rudi Hwang and Takahiro Shinkai and Jan Volavka and Pal Czobor and Sheitman, {Brian B.} and Lindenmayer, {Jean Pierre} and Leslie Citrome and McEvoy, {Joseph Patrick} and Lieberman, {Jeffrey A.} and Kennedy, {James L.}",
note = "Funding Information: NIMH grant (R10 MH53550) and CIHR provided the principal support for this project. Additional support was provided by the UNC-Mental Health and Neuroscience Clinical Research Center (MH MH33127) and the Foundation of Hope, Raleigh North Carolina. We thank Janssen Pharmaceutica Research Foundation, Eli Lilly and Company, Novartis Pharmaceuticals Corporation, and Merck and Co., Inc. for their generous gifts of medications. Eli Lilly and Company contributed supplemental funding that covered approximately 18% of the total cost of the study. However, overall experimental design, data acquisition, statistical analyses, and interpretation of the results were implemented without any input from any of the pharmaceutical companies. Linda Kline, RN, MS, CS was the chief coordinator of the entire project. Dr. Vincenzo De Luca is recipient of American Foundation for Suicide Prevention (AFSP) fellowship.",
year = "2005",
month = apr,
doi = "10.1016/j.phrs.2004.10.013",
language = "English (US)",
volume = "51",
pages = "381--384",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press Inc.",
number = "4",
}